{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:15:17Z","timestamp":1765808117897,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hairy cell leukemia (HCL) treatment in elderly, frail subjects is still unsatisfactory, and interferons, old-fashioned therapies, can be effectively used in this subset of patients. Here, to the best of our knowledge, we report for the first time an old, frail HCL patient effectively and safely treated with pegylated interferon-\u03b1-2a in monotherapy as a first-line treatment. At diagnosis, the patient arrived in a life-threating condition due to severe neutropenia and splenomegaly with high risk of splenic rupture. However, splenectomy was proposed and refused by the patient; therefore, a therapy with pegylated interferon-\u03b1-2a was initiated. After six months of therapy, the patient displayed the disappearance of palpable splenomegaly and of peripheral hairy cells at morphological examination without any drug-related adverse event. Our case report supports the use of pegylated interferon-\u03b1-2a in monotherapy as an effective and safe alternative therapeutic option in frail, elderly patients not eligible for purine analogous or targeted therapies.<\/jats:p>","DOI":"10.3390\/jcm12010193","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T03:03:31Z","timestamp":1672110211000},"page":"193","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-\u03b1-2A"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2590-0529","authenticated-orcid":false,"given":"Danilo","family":"De Novellis","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"},{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-6848","authenticated-orcid":false,"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"},{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Ciccone","sequence":"additional","affiliation":[{"name":"Radiology Unit, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Erra","sequence":"additional","affiliation":[{"name":"Radiology Unit, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"De Vita","sequence":"additional","affiliation":[{"name":"Radiology Unit, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Picone","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Serio","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5861-8984","authenticated-orcid":false,"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"},{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.25653","article-title":"Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Maitre","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/cyto.b.22096","article-title":"Biclonality in hairy cell leukemia: Co-occurrence of CD10+ and CD10\u2212 clones with different surface membrane immunoglobulin expression","volume":"102","author":"Gorrese","year":"2022","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/cyto.b.21980","article-title":"A rare biclonal Hairy Cell Leukemia disclosed by an integrated diagnostic approach: A case report","volume":"100","author":"Vittoria","year":"2021","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/annonc\/mdv200","article-title":"Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis; treatment and follow-up","volume":"26","author":"Robak","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00277-014-2140-y","article-title":"Recommendations of the SFH (French Society of Haematology) for the diagnosis; treatment and follow-up of hairy cell leukaemia","volume":"93","author":"Cornet","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2012.078071","article-title":"Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia","volume":"98","author":"Tiacci","year":"2013","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/10428194.2011.573033","article-title":"Historical treatments of in hairy cell leukemia; splenectomy and interferon: Past and current uses","volume":"52","author":"Habermann","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-022-00702-9","article-title":"Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study","volume":"12","author":"Pagano","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1080\/10428194.2019.1608536","article-title":"Hairy cell leukemia: Present and future directions","volume":"60","author":"Kreitman","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"D\u2019Addona, M., Giudice, V., Pezzullo, L., Ciancia, G., Baldi, C., Gorrese, M., Bertolini, A., Campana, A., Fresolone, L., and Manzo, P. (2022). Hodgkin Lymphoma and Hairy Cell Leukemia Arising from Chronic Lymphocytic Leukemia: Case Reports and Literature Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164674"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study","volume":"13","author":"Grever","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2003-02-0630","article-title":"Rituximab in relapsed or refractory hairy cell leukemia","volume":"102","author":"Thomas","year":"2003","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1080\/10428194.2021.1929959","article-title":"Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia","volume":"62","author":"Yurkiewicz","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kreitman, R.J., Moreau, P., Ravandi, F., Hutchings, M., Gazzah, A., Michallet, A.S., Wainberg, Z.A., Stein, A., Dietrich, S., and de Jonge, M.J.A. (2022). Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood, 2021013658.","DOI":"10.1182\/blood.2021013658"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1182\/blood.2020009688","article-title":"Phase 2 study of ibrutinib in classic and variant hairy cell leukemia","volume":"137","author":"Rogers","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1038\/bcj.2014.3","article-title":"Hairy cell leukemia: Short review; today\u2019s recommendations and outlook","volume":"4","author":"Maevis","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1034\/j.1600-0609.2000.90014.x","article-title":"Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: A long-term follow-up analysis","volume":"64","author":"Damasio","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/ageing\/afx162","article-title":"Frailty index as a predictor of mortality: A systematic review and meta-analysis","volume":"47","author":"Kojima","year":"2018","journal-title":"Age Ageing"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a, F.G., Theou, O., Wallace, L., Brothers, T.D., Gill, T.M., Gahbauer, E.A., Kirkland, S., Mitnitski, A., and Rockwood, K. (2014). Comparison of alternate scoring of variables on the performance of the frailty index. BMC Geriatr., 14.","DOI":"10.1186\/1471-2318-14-25"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2022042","DOI":"10.4084\/MJHID.2022.042","article-title":"Post-therapy B Regulatory Cells Might early Predict Relapse in Hodgkin Lymphoma","volume":"14","author":"Giudice","year":"2022","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Lindner","year":"2003","journal-title":"Apoptosis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e05919","DOI":"10.1002\/ccr3.5919","article-title":"Kaposi\u2019s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy","volume":"10","author":"Pezzullo","year":"2022","journal-title":"Clin. Case Rep."},{"key":"ref_26","first-page":"1056","article-title":"Mechanism of interferon action in hairy cell leukemia: A model of effective cancer biotherapy","volume":"52","author":"Vedantham","year":"1992","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/hematolrep14020020","article-title":"Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon \u03b1-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution","volume":"14","author":"Furlan","year":"2022","journal-title":"Hematol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bjh.17440","article-title":"The current role of interferon in hairy cell leukaemia: Clinical and molecular aspects","volume":"194","author":"Assanto","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_29","first-page":"152","article-title":"Hairy-cell leukemia and alpha-interferon treatment: Long-term responders","volume":"82","author":"Zinzani","year":"1997","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1600-0609.2008.01190.x","article-title":"Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia","volume":"82","author":"Benz","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood.V69.3.872.872","article-title":"Durability of responses to interferon alfa-2b in advanced hairy cell leukemia","volume":"69","author":"Ratain","year":"1987","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1521-6926(02)00084-1","article-title":"Interferon in the treatment of hairy-cell leukemia","volume":"16","author":"Ahmed","year":"2003","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/273759a0","article-title":"Enhanced NK cell activity in mice injected with interferon and interferon inducers","volume":"273","author":"Gidlund","year":"1978","journal-title":"Nature"},{"key":"ref_34","first-page":"951","article-title":"Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin\u2019s lymphoma","volume":"86","author":"Sacchi","year":"2001","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12254-016-0269-1","article-title":"Long-term treatment of hairy cell leukemia with interferon-\u03b1: Still a viable therapeutic option","volume":"9","author":"Bohn","year":"2016","journal-title":"Memo"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E180","DOI":"10.1002\/ajh.25474","article-title":"Low-dose vemurafenib in hairy cell leukemia patients with active infection","volume":"94","author":"Bohn","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s00277-021-04662-1","article-title":"Impact of rituximab on COVID-19 outcomes","volume":"100","author":"Levavi","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.leukres.2017.01.006","article-title":"Pegylated interferon alpha\u20142a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial","volume":"54","author":"Gowin","year":"2017","journal-title":"Leuk Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-alpha2b: Pharmacokinetics; pharmacodynamics; safety; and preliminary efficacy data. Hepatitis C Intervention Therapy Group","volume":"68","author":"Glue","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-alpha therapy","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm. World Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10717540600814402","article-title":"Pharmacokinetic consequences of pegylation","volume":"13","author":"Hamidi","year":"2006","journal-title":"Drug. Deliv."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/193\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:52:11Z","timestamp":1760147531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jcm12010193"],"URL":"https:\/\/doi.org\/10.3390\/jcm12010193","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}